Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
25
NRC Quote, Financials, Valuation and Earnings
Last price:
$10.83
Seasonality move
:
5.89%
Day range:
$10.24 - $10.91
52-week range:
$9.76 - $35.81
Dividend yield:
4.48%
P/E ratio:
10.21x
P/S ratio:
1.78x
P/B ratio:
7.86x
Volume:
75.1K
Avg. volume:
88.4K
1-year change:
-68.09%
Market cap:
$246M
Revenue:
$143.1M
EPS (TTM):
$1.05
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, National Research has -- downside to fair value with a price target of -- per share.
NRC vs. S&P 500
-
Over the past 5 trading days, National Research has underperformed the S&P 500 by -2.76% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
National Research does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
National Research revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter National Research reported revenues of $36.9M.
Earnings Growth
-
National Research earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter National Research reported earnings per share of $0.28.
Enterprise value:
304.4M
EV / Invested capital:
--
Price / LTM sales:
1.78x
EV / EBIT:
8.63x
EV / Revenue:
2.13x
PEG ratio (5yr expected):
5.51x
EV / Free cash flow:
15.87x
Price / Operating cash flow:
13.28x
Enterprise value / EBITDA:
7.37x
Gross Profit (TTM):
$86.1M
Return On Assets:
19.77%
Net Income Margin (TTM):
17.32%
Return On Equity:
64.54%
Return On Invested Capital:
28.86%
Operating Margin:
25.98%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $151.6M | $148.6M | $143.1M | $38M | $36.9M | |
| Gross Profit | $94.5M | $92.6M | $86.1M | $24.2M | $22.6M | |
| Operating Income | $46.5M | $40M | $35.2M | $11.7M | $9.6M | |
| EBITDA | $49.3M | $46.7M | $41.3M | $13.2M | $11.1M | |
| Diluted EPS | $1.27 | $1.25 | $1.05 | $0.36 | $0.28 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $54.1M | $73.7M | $43.7M | $24.4M | $19.6M | |
| Total Assets | $133.4M | $157.5M | $130.5M | $122.4M | $132.5M | |
| Current Liabilities | $31.7M | $40.4M | $33.4M | $36.2M | $35.9M | |
| Total Liabilities | $69.1M | $72.2M | $58.4M | $73.5M | $101.3M | |
| Total Equity | $64.3M | $85.3M | $72M | $49M | $31.3M | |
| Total Debt | $30.6M | $26.5M | $22.2M | $36.7M | $62.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $36.3M | $38.1M | $34.6M | $11.7M | $6.4M | |
| Cash From Investing | -$9.8M | -$15.8M | -$20.3M | -$3.8M | -$4.4M | |
| Cash From Financing | -$55.6M | -$40.7M | -$16.8M | -$5.1M | -$1.2M | |
| Free Cash Flow | $26.4M | $22.3M | $19.2M | $7.9M | $1.9M | |
NRC
Sector
Market Cap
$246M
$35M
Price % of 52-Week High
29.94%
44.47%
Dividend Yield
4.48%
0%
Shareholder Yield
8.41%
-0.9%
1-Year Price Total Return
-68.09%
-38.53%
Beta (5-Year)
0.414
0.738
Dividend yield:
4.48%
Annualized payout:
$0.48
Payout ratio:
46.22%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.61
200-day SMA
Sell
Level
$18.54
Bollinger Bands (100)
Sell
Level
13.15 - 18.41
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Sell
Level
$11.45
Relative Strength Index (RSI14)
Sell
Level
34.33
ADX Line
Sell
Level
32.22
Williams %R
Neutral
Level
-73.3793
50-day SMA
Sell
Level
$13.78
MACD (12, 26)
Sell
Level
-0.98
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
7.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.0433)
Buy
CA Score
(Annual)
Level (0.3726)
Buy
Beneish M-Score
(Annual)
Level (-2.9872)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.3611)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
Stock Forecast FAQ
In the current month, NRC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NRC average analyst price target in the past 3 months is --.
-
Where Will National Research Stock Be In 1 Year?
According to analysts, the consensus estimate is that National Research share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About National Research?
Analysts are divided on their view about National Research share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that National Research is a Sell and believe this share price will rise from its current level to --.
-
What Is National Research's Price Target?
The price target for National Research over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NRC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for National Research is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NRC?
You can purchase shares of National Research via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase National Research shares.
-
What Is The National Research Share Price Today?
National Research was last trading at $10.83 per share. This represents the most recent stock quote for National Research. Yesterday, National Research closed at $10.72 per share.
-
How To Buy National Research Stock Online?
In order to purchase National Research stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 28
Saia [SAIA] is down 3.49% over the past day.
Sell
48
APPF alert for Apr 28
AppFolio [APPF] is up 5.02% over the past day.
Sell
15
KNSL alert for Apr 28
Kinsale Capital Group [KNSL] is up 0.99% over the past day.
